Literature DB >> 21552421

Varied pathways of stage IA lung adenocarcinomas discovered by integrated gene expression analysis.

Chengwen Chen1, Xuping Fu, Deqiang Zhang, Yuan Li, Yi Xie, Yao Li, Yan Huang.   

Abstract

BACKGROUND: Discovery of the progression-associated genes and pathways in lung adenocarcinoma (LAD) has important implications in understanding the molecular mechanism of tumor development. However, few studies had been performed to focus on the changes of pathways in lung adenocarcinoma development using microarray expression profile. RESULT: We performed a meta-analysis of 4 LAD microarray datasets encompassing 353 patients to reveal differentially expressed genes (DEGs) between normal lung tissues and LAD of different stages. Overall, 1 838 genes were found to be dys-regulated, and the adipogenesis, circadian rhythm, and Id pathways were significantly changed. Interestingly, most of the genes from the same gene family (such as Interleukin receptor, Matrix metallopeptidase, Histone cluster and Minichromosome maintenance complex component families) were found to be up-regulated (or down-regulated). Real-time PCR (qRT-PCR) was applied to validate the expression of randomly selected 18 DEGs in LAD cell lines. In the pathway analysis among stages, Oxidative stress, Glycolysis/Gluconeogenesis and Integrin-mediated cell adhesion pathways, which were involved in cancer cell proliferation and metastasis, were showed to be significantly regulated in stages other than IA.
CONCLUSION: Genes involved in adipogenesis and Id pathways might play important roles in development of LADs. The similar trend of expression of the gene family members suggested coordinate regulation in tumor progression. Three pathways (Oxidative stress, Glycolysis/Gluconeogenesis and Integrin-mediated cell adhesion pathways) significantly regulated in stages other than stage IA suggested that genes and pathways conferring invasive character might be activated in the preinvasive stage IB, while the Oxidative stress and the Glycolysis/Gluconeogenesis pathways might have strong connections to cisplatin-based chemotherapy. The insignificantly regulated three pathways in stage IA might be used in early-stage detection of LAD.

Entities:  

Keywords:  lung adenocarcinoma; meta-analysis; pathway; sample size

Mesh:

Year:  2011        PMID: 21552421      PMCID: PMC3088877          DOI: 10.7150/ijbs.7.551

Source DB:  PubMed          Journal:  Int J Biol Sci        ISSN: 1449-2288            Impact factor:   6.580


  79 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Identification of the osteopontin gene as a direct target of TP53.

Authors:  Ichiro Morimoto; Yasushi Sasaki; Setsuko Ishida; Kohzoh Imai; Takashi Tokino
Journal:  Genes Chromosomes Cancer       Date:  2002-03       Impact factor: 5.006

Review 3.  Id proteins at the cross-road of development and cancer.

Authors:  A Lasorella; T Uo; A Iavarone
Journal:  Oncogene       Date:  2001-12-20       Impact factor: 9.867

Review 4.  DNA microarrays in clinical oncology.

Authors:  Sridhar Ramaswamy; Todd R Golub
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

Review 5.  The Warburg effect and mitochondrial stability in cancer cells.

Authors:  Vladimir Gogvadze; Boris Zhivotovsky; Sten Orrenius
Journal:  Mol Aspects Med       Date:  2009-12-06

6.  Loss of alveolar basement membrane type IV collagen alpha3, alpha4, and alpha5 chains in bronchioloalveolar carcinoma of the lung.

Authors:  K Y Nakano; K I Iyama; T Mori; M Yoshioka; T Hiraoka; Y Sado; Y Ninomiya
Journal:  J Pathol       Date:  2001-08       Impact factor: 7.996

7.  Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3.

Authors:  Carly St Germain; Nima Niknejad; Laurie Ma; Kyla Garbuio; Tsonwin Hai; Jim Dimitroulakos
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

Review 8.  Fyn: a novel molecular target in cancer.

Authors:  Yoshihito D Saito; Ana R Jensen; Ravi Salgia; Edwin M Posadas
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

Review 9.  Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

Authors:  Dunyaporn Trachootham; Jerome Alexandre; Peng Huang
Journal:  Nat Rev Drug Discov       Date:  2009-05-29       Impact factor: 84.694

10.  PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways.

Authors:  Yong Luo; Fubo Liang; Zhong-Yin Zhang
Journal:  Biochemistry       Date:  2009-03-03       Impact factor: 3.162

View more
  7 in total

1.  Defining the molecular signature of chemotherapy-mediated lung tumor phenotype modulation and increased susceptibility to T-cell killing.

Authors:  Sofia R Gameiro; Jorge A Caballero; James W Hodge
Journal:  Cancer Biother Radiopharm       Date:  2012-02-08       Impact factor: 3.099

Review 2.  The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.

Authors:  Qian Qiao; Weiguo Hu
Journal:  Lung       Date:  2013-04-18       Impact factor: 2.584

3.  Meta-analysis of gene expression profiles indicates genes in spliceosome pathway are up-regulated in hepatocellular carcinoma (HCC).

Authors:  Weijin Xu; Huixing Huang; Long Yu; Lihuan Cao
Journal:  Med Oncol       Date:  2015-03-03       Impact factor: 3.064

4.  Development and validation of a prognostic gene-expression signature for lung adenocarcinoma.

Authors:  Yun-Yong Park; Eun Sung Park; Sang Bae Kim; Sang Cheol Kim; Bo Hwa Sohn; In-Sun Chu; Woojin Jeong; Gordon B Mills; Lauren Averett Byers; Ju-Seog Lee
Journal:  PLoS One       Date:  2012-09-07       Impact factor: 3.240

5.  KLHL21, a novel gene that contributes to the progression of hepatocellular carcinoma.

Authors:  Lei Shi; Wenfa Zhang; Fagui Zou; Lihua Mei; Gang Wu; Yong Teng
Journal:  BMC Cancer       Date:  2016-10-21       Impact factor: 4.430

6.  Exhaled metabolic markers and relevant dysregulated pathways of lung cancer: a pilot study.

Authors:  Yingchang Zou; Yanjie Hu; Zaile Jiang; Ying Chen; Yuan Zhou; Zhiyou Wang; Yu Wang; Guobao Jiang; Zhiguang Tan; Fangrong Hu
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

7.  Prognostic Implications and Immune Infiltration Analysis of ALDOA in Lung Adenocarcinoma.

Authors:  Guojun Lu; Wen Shi; Yu Zhang
Journal:  Front Genet       Date:  2021-12-03       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.